Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

reduces renal damage

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (2) Calcium Channel (1) Caspase (1) Endogenous Metabolite (1) Farnesyl Transferase (1) Ferroptosis (1) Guanylate Cyclase (1) HIF/HIF Prolyl-Hydroxylase (2) IRE1 (1) JNK (1) Keap1-Nrf2 (2) MDM-2/p53 (2) NF-κB (1) NOD-like Receptor (NLR) (2) Reactive Oxygen Species (ROS) (3) Reference Standards (1) TRP Channel (2) Xanthine Oxidase (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Inflammation/Immunology (6) Metabolic Disease (6) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0321

Caftaric acid trans-Caftaric acid	Others	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Caftaric acid (trans-Caftaric acid) is a polyphenolic antidiuretic, antioxidant and anti-apoptotic agent that can be hydrolyzed by intestinal microbial esterases. Caftaric acid exerts its antioxidant and potential anti-inflammatory effects mainly through intestinal microbial metabolism. Caftaric acid can reduce renal damage, restore electrolyte balance, renal function indicators and antioxidant enzyme activities in a rat albinism model, and further exert anti-oxidative stress and anti-inflammatory activities .

HY-B0639

Amifostine 10+ Cited Publications WR2721	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .

HY-B0639A

Amifostine trihydrate 10+ Cited Publications WR2721 trihydrate	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .

HY-175081

8-Br-cADPR sodium salt 8-Bromo-Cyclic ADP-Ribose sodium salt	TRP Channel	Metabolic Disease
8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose) sodium salt, a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR sodium salt reduces renal damage and the expression of caspase-3 and TRPM2 .

HY-117962

(Rac)-BI 703704	Guanylate Cyclase	Metabolic Disease
(Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy .

HY-105271

S-312-d S-(+)-S-312-d	Calcium Channel	Others
S-312-d (S-(+)-S-312-d) is a calcium channel blocker with the activity of protecting the kidney from ischemic acute renal failure. S-312-d (0.01-0.1mg/kg b.wt. iv) administered before ischemia has a dose-dependent protective effect on ischemia-induced renal damage, improves the survival rate of ischemic rats, and reduces renal cortical edema and the increase in renal tissue calcium content.

HY-134579

Chaetomellic acid A	Farnesyl Transferase	Inflammation/Immunology
Chaetomellic acid A can be isolated from Chaetomella acutiseta. Chaetomellic acid A is a specific inhibitor of farnesyl-protein transferase. Chaetomellic acid A decreases oxidative stress-induced apoptosis in cells. Chaetomellic acid A reduces renal damage after unilateral ureteral obstruction (UUO) in mice .

HY-174318

NARS-3′	Xanthine Oxidase	Metabolic Disease
NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC₅₀ of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.

HY-117804

8-Br-cADPR 8-Bromo-Cyclic ADP-Ribose	TRP Channel	Neurological Disease Metabolic Disease
8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose), a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR reduces renal damage and the expression of caspase-3 and TRPM2 .

HY-176238

CX116	Apoptosis	Metabolic Disease Cancer
CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity, and can significantly protect renal tissue from Cisplatin (HY-17394)-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI) .

HY-19696B

Tauroursodeoxycholate dihydrate Maximum Cited Publications 79 Publications Verification Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .

HY-113298

Citraconic acid 2 Publications Verification Methylmaleic acid	NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
Citraconic acid (Methylmaleic acid) is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052) .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-113298R

Citraconic acid (Standard) Methylmaleic acid (Standard)	Reference Standards NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
Citraconic acid (Methylmaleic acid) (Standard) is the analytical standard of Citraconic acid (HY-113298). This product is intended for research and analytical applications. Citraconic acid is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052) .

Cat. No.	Product Name

HY-L145

Antihypertensive Compound Library	772 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 772 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

772 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 772 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Category	Target	Chemical Structure